Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis
- First Posted Date
- 2006-08-08
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 14
- Registration Number
- NCT00361634
- Locations
- 🇬🇧
Research Site, London, United Kingdom
An Open Label Treatment Extension Study of AMG 706
- First Posted Date
- 2006-08-07
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 94
- Registration Number
- NCT00360867
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Phase 3
Completed
- Conditions
- Congestive Heart FailureVentricular DysfunctionHeart FailureAnemiaCardiovascular Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2278
- Registration Number
- NCT00358215
- Locations
- 🇬🇧
Research Site, York, United Kingdom
A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer
Phase 2
Terminated
- Conditions
- Breast TumorsBreast CancerLocally Recurrent and Metastatic Breast CancerBreast Neoplasms
- Interventions
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 282
- Registration Number
- NCT00356681
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Etanercept
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 468
- Registration Number
- NCT00356590
16.0040 Ankylosing Spondylitis Study
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 257
- Registration Number
- NCT00356356
Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer
Phase 1
Withdrawn
- Conditions
- OncologyNon-Small Cell Lung Cancer
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Amgen
- Registration Number
- NCT00352950
An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 115
- Registration Number
- NCT00346294
Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1186
- Registration Number
- NCT00339183
Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis
Phase 4
Completed
- Conditions
- Psoriasis
- Interventions
- Biological: etanercept
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 246
- Registration Number
- NCT00332332
© Copyright 2025. All Rights Reserved by MedPath